## Edgar Filing: ARRAY BIOPHARMA INC - Form 4

## ARRAY BIOPHARMA INC Form 4 November 26, 2002

FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					OMB APPROVAL			
o Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. <i>See</i> Instruction 1(b). (Print or Type Responses)	Filed pursuant to Section 17(a) of	STATEMEN GES IN BENEFIC o Section 16(a) of the S of the Public Utility Hol 30(h) of the Investmen		OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response 0.5					
1. Name and Address of Report SNITMAN DAVID	ing Person* 2. L.	Issuer Name and Tick ARRAY BIOPHARM	ter of fracing symbol	(Chec	onship of R k all applica Director		n(s) to Issuer Owner		
(Last) (First) 3200 WALNUT STREET	(Middle) 3.	I.R.S. Identification Number of Reporting Person, if an entity (voluntary)	<ol> <li>Statement for Month/Day/Year</li> <li>11/25/02</li> </ol>	X_OfficerOther (give title (specify below) below) CHIEF OPERATING OFFICER, VICE PRESIDENT, BUSINESS DEVELOPMENT			ify below) , VICE		
(Street) BOULDER CO	80301		5. If Amendment, Date of Original (Month/Day/Year)	(Chec	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State)	(Zip) Tal	ble I Non-Derivative	Securities Acquired, Dispo	sed of, or I	Beneficially	y Owned			
1. Title of 2. Transaction 2. Security Date (Instr. 3)	2A. Deemed Execution Da if any		<ol> <li>Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</li> </ol>	Owne Follov Repor Trans	ities ficially ed wing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	<ol> <li>Nature of Indirect Beneficial Ownership (Instr. 4)</li> </ol>		
(Month/Day/	Year) (Month/Day/	Year)Code V	Amount (A) Price or (D)						
COMMON 11/25/02 STOCK	11/25/02	S(1)	10,000 D \$8.5375	1,339	,011	D			
				100,0	00	Ι	(2)		

	Indext       Table II       Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)									
Title of Derivative2. Conversion 3. Trans. or ExerciseSecurity (Instr. 3)Price of Derivative Security	action Date 3A. th/Day/Year)	Deemed Execution Date, if any (Month/Day/Year)	Code		Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			
			Code	V	(A) (D)		Date Exercisable	Expiration Date		
<ul> <li>Title and Amount of Underlying Securities (Instr. 3 and 4)</li> </ul>	8. Price of Der Security (Instr. 5)	Deri Secu Ben Foll Trar	nber of ivative irities eficially Ow owing Repo isaction(s) tr. 4)	med	0. Ownership Derivative Securities: J (D) or Indir (Instr. 4)	Direct	Ben Ow	ure of Indirec eficial nership tr. 4)		

Explanation of Responses:

(1)

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on Septermber 30, 2002.

(2)

These shares are held in trust for the benefit of the reporting person's children.

/s/ David L. Snitman

\*\*Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. *http://www.sec.gov/divisions/corpfin/forms/form4.htm* Last update: 09/05/2002

November 26, 2002 Date